Founded in 2006 and headquartered in San Diego, Mesa Verde Venture Partners focuses on drug discovery/tools, medical devices and diagnostics, and healthcare information technology. The fund has $13.1 million in committed capital and aims to reach a target size of $15 to $20 million. It primarily invests in startups in the southwest region of the United States, with a preference for companies aged 6-10 years. Mesa Verde Venture Partners has a portfolio that includes Lineagen, Medipacs, and Traversa Therapeutics, and it typically invests in rounds with 4-5 participants.